| No endocrine treatment (n=206) | Endocrine treatment without OS (n=2018) | Endocrine treatment with medical OS (n=282) | Endocrine treatment with BSO (n=234) | P value |
n (%) | n (%) | n (%) | n (%) | ||
Follow-up | |||||
Median | 37.1 | 64.1 | 60.1 | 67.3 | |
Range | 0.6–105.9 | 0.5–115.1 | 3.1–108.3 | 6.2–108.4 | |
IQR | 7.5–58.2 | 48.9–82.7 | 49.2–77.7 | 51.9–84.4 | |
Age at diagnosis | |||||
Median (mean) | 45 (43.9) | 45(44) | 43 (42.2) | 45 (44.1) | <0.001* |
Range | 20–56 | 20–60 | 24–59 | 26–55 | |
IQR | 41–48 | 40–49 | 37–48 | 40–48 | |
Year of diagnosis | |||||
2010 | 40 (7.5) | 404 (76.2) | 41 (7.7) | 45 (8.5) | <0.001 |
2011 | 31 (5.8) | 421 (78.4) | 39 (7.3) | 46 (8.6) | |
2012 | 37 (7.4) | 373 (74.9) | 46 (9.2) | 42 (8.4) | |
2013 | 42 (7) | 442 (74) | 69 (11.6) | 44 (7.4) | |
2014 | 56 (9.7) | 378 (65.4) | 87 (15.1) | 57 (9.9) | |
Family history† | |||||
No | 85 (7) | 922 (75.7) | 116 (9.5) | 95 (7.8) | 0.202 |
Yes | 114 (7.9) | 1041 (72) | 157 (10.9) | 133 (9.2) | |
Unknown | 7 | 55 | 9 | 6 | |
Live children | |||||
No | 62 (8.3) | 556 (74.2) | 79 (10.5) | 52 (6.9) | 0.263 |
Yes | 144 (7.2) | 1462 (73.4) | 203 (10.2) | 182 (9.1) | |
Histology | |||||
Any ductal no lobular | 166 (7.6) | 1606 (73.4) | 232 (10.6) | 184 (8.4) | 0.008 |
Any lobular no ductal | 19 (7.1) | 190 (70.9) | 34 (12.7) | 25 (9.3) | |
Lobular and ductal | 8 (4.5) | 135 (76.7) | 11 (6.3) | 22 (12.5) | |
Inflammatory | 0 (0) | 9 (75) | 2 (16.7) | 1 (8.3) | |
Other | 13 (13.5) | 78 (81.3) | 3 (3.1) | 2 (2.1) | |
Grade† | |||||
G1 | 27 (13.8) | 155 (79.1) | 7 (3.6) | 7 (3.6) | <0.001 |
G2 | 35 (5.5) | 478 (75.8) | 72 (11.4) | 46 (7.3) | |
G3 | 113 (6.7) | 1229 (72.6) | 186 (11) | 166 (9.8) | |
Unknown | 31 | 156 | 17 | 15 | |
LN pos exact† | |||||
No | 163 (9.3) | 1319 (75.5) | 141 (8.1) | 123 (7) | <0.001 |
Yes | 43 (4.3) | 698 (70.4) | 140 (14.1) | 110 (11.1) | |
Unknown | 1 | 1 | 1 | ||
Stage (unknown removed) | |||||
I | 135 (9.8) | 1048 (76.1) | 107 (7.8) | 87 (6.3) | <0.001 |
II | 47 (5.6) | 634 (74.9) | 86 (10.2) | 79 (9.3) | |
III | 16 (5.2) | 193 (62.9) | 55 (17.9) | 43 (14) | |
Chemotherapy | |||||
No | 138 (13.5) | 729 (71.5) | 88 (8.6) | 65 (6.4) | <0.001 |
Yes | 68 (4) | 1289 (74.9) | 194 (11.3) | 169 (9.8) | |
HER-2 targeted | |||||
None | 183 (7.9) | 1698 (73.6) | 242 (10.5) | 183 (7.9) | <0.001 |
Trastuzumab | 17 (5.2) | 256 (78) | 25 (7.6) | 30 (9.1) | |
Trastuzumab+other | 6 (5.7) | 64 (60.4) | 15 (14.2) | 21 (19.8) |
Percentages are calculated by row.
*p values for continuous variables are calculated using Kruskal-Wallis test, if not otherwise labeled.
†For these variables the unknowns are not considered in the percentage reporting and the test for p value.
BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; IQR, interquartile range; LN, lymph node; OS, ovarian suppression.